Patent application number | Description | Published |
20090060917 | Carbamate Stereoisomer - The compound of formula (I) | 03-05-2009 |
20090060922 | Acetamide Stereoisomer - The compound of formula (I) | 03-05-2009 |
20100215589 | Carbamate Stereoisomer - The compound of formula (I) | 08-26-2010 |
20110172177 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE - The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A | 07-14-2011 |
20110245193 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE - Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine A | 10-06-2011 |
20110245195 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 10-06-2011 |
20110251151 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE - Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine A | 10-13-2011 |
20130196940 | ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAH- YDROFURAN-2-YL)} METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF - The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A. | 08-01-2013 |
20130296607 | Acetamide Stereoisomer - The compound of formula (I) | 11-07-2013 |
20140018314 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 01-16-2014 |
20140135300 | Acetamide Stereoisomer - The compound of formula (I) | 05-15-2014 |
20140271876 | OPHTHALMIC FORMULATIONS - The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof. | 09-18-2014 |
20140275128 | METHOD OF PROVIDING OCULAR NEUROPROTECTION - Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for preventing, reducing or treating retinal ganglion cell damage comprising administering an effective amount of a purine derivative to a subject in need thereof. | 09-18-2014 |
20150038448 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE - The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A | 02-05-2015 |
20150080330 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 03-19-2015 |